|
|
Volumn 4, Issue 2, 2009, Pages 65-66
|
|
The toxicities of modern targeted therapies-learning from the price of progress
a,b
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABELSON KINASE;
BCR ABL PROTEIN;
DASATINIB;
EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;
IMATINIB;
MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;
NILOTINIB;
PLATELET DERIVED GROWTH FACTOR RECEPTOR;
PROTEIN KINASE SYK INHIBITOR;
PROTEIN TYROSINE KINASE INHIBITOR;
STEM CELL FACTOR;
VASCULOTROPIN INHIBITOR;
CANCER CHEMOTHERAPY;
CARDIOTOXICITY;
CHRONIC MYELOID LEUKEMIA;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TARGETING;
EDITORIAL;
GASTROINTESTINAL HEMORRHAGE;
HUMAN;
HUMAN GENOME PROJECT;
LUNG TOXICITY;
MAXIMUM TOLERATED DOSE;
MOLECULAR TARGETED THERAPY;
ONCOLOGY;
PNEUMONIA;
PRIORITY JOURNAL;
SKIN TOXICITY;
DRUG DELIVERY SYSTEMS;
HEMORRHAGE;
HUMANS;
INTERDISCIPLINARY COMMUNICATION;
LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;
LUNG;
PIPERAZINES;
PROTEIN KINASE INHIBITORS;
PROTEIN KINASES;
PYRIMIDINES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
SIROLIMUS;
SKIN;
THIAZOLES;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
|
|
EID: 67349139594
PISSN: 17762596
EISSN: 1776260X
Source Type: Journal
DOI: 10.1007/s11523-009-0105-1 Document Type: Editorial |
|
Times cited : (4)
|
|
References (0)
|
